Magnetic poly(d,l-lactide) nanoparticles loaded with aliskiren: A promising tool for hypertension treatment

In this study anti-hypertensive drug called aliskiren was encapsulated in magnetic poly(d,l-lactide) nanoparticles by the modified nanoprecipitation method. The effect of magnetite and drug concentrations on the size distribution and zeta potential of polymer nanoparticles was investigated. The optimized loadings were as follows: theoretical magnetite loading was 20mg/100mg polymer nanoparticles and aliskiren was encapsulated in magnetic poly(d,l-lactide) nanoparticles at theoretical loading 0.6mg aliskiren/100mg magnetic polymer nanoparticles. The physicochemical characteristics of nanoparticles were studied, with spherical shape of nanoparticles sized between 58 and 227nm being one of the observed results. Differential scanning calorimetry and infrared spectroscopy confirmed that aliskiren was successfully identified in the magnetic poly(d,l-lactide) nanoparticles. The in vivo experiments indicated that encapsulated aliskiren decreased blood pressure of the studied male spontaneously hypertensive rat even more significantly than common administered drug. •Anti-hypertensive drug called aliskiren was encapsulated in magnetic poly(D,L-lactide) nanoparticles by modified nanoprecipitation method.•The optimisation of magnetite and drug loading with regard to the size distribution and zeta potential was investigated.•The physicochemical characteristics of nanoparticles were studied by different techniques.•The in vivo experiments indicated that encapsulated aliskiren decreased blood pressure of the studied male spontaneously hypertensive rat even more significantly than common administered drug.